ruxolitinib

Known as: (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile 
An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
05010015020102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile… (More)
  • figure 1
  • table 1
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated rapid reductions in splenomegaly and marked… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The Janus kinase (JAK)-inhibitor ruxolitinib decreases constitutional symptoms and spleen size of myelofibrosis (MF) patients by… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 5
Is this relevant?
2013
2013
n engl j med 369;7 nejm.org august 15, 2013 681 Portion Cap Rule in the first place. Does the board believe that it has… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND The molecular causes of many hematologic cancers remain unclear. Among these cancers are chronic neutrophilic leukemia… (More)
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2013
2013
n engl j med 369;2 nejm.org july 11, 2013 197 technique and that centers and surgeons were selected because of their experience… (More)
  • table 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and… (More)
  • table 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
n engl j med 365;15 nejm.org october 13, 2011 1455 The responsibility of ODAC is to carefully consider the scientific data… (More)
  • figure 1
Is this relevant?